RCT of Gastric ESD With or Without Epineprhine Added Solution

Last updated: April 30, 2025
Sponsor: Chinese University of Hong Kong
Overall Status: Completed

Phase

3

Condition

Gastric Cancer

Stomach Cancer

Digestive System Neoplasms

Treatment

Endoscopic submucosal dissection

Epinephrine

Clinical Study ID

NCT04032119
EPI-ESD RCT01
  • Ages > 20
  • All Genders

Study Summary

This is an international multi-center randomised controlled study comparing outcomes of gastric endoscopic submucosal dissection (ESD) with or without addition of epinephrine in the submucosal injection solution.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Selection criteria: Presence of intramucosal neoplastic lesions in the stomachplanning for endoscopic submucosal dissection (Vienna Classification Category 3 and 4 lesion)

  • Target subjects receiving sufficient briefing from the attending physician regardingthe content of this study and providing informed consent for participation

Exclusion

Exclusion Criteria:

  • Recurrent / remnant lesion after previous endoscopic resection

  • Lesions arising from surgical anastomotic site, such as gastrojejunostomy /gastroduodenostomy.

  • Marked electrolyte abnormalities

  • Hemostatic or coagulative abnormalities

  • Patient on anti-coagulant agents, including warfarin and other direct oralanti-coagulants (those on antiplatelet can be included)

  • Failure of vital organ (heart, lungs, liver, or kidneys) function

  • Allergic to components of injection solutions: Epinephrine, hyaluronic acid etc

  • Other cases deemed by the examining physician as unsuitable for safe treatment

Study Design

Total Participants: 800
Treatment Group(s): 2
Primary Treatment: Endoscopic submucosal dissection
Phase: 3
Study Start date:
January 10, 2020
Estimated Completion Date:
January 31, 2023

Study Description

Endoscopic submucosal dissection (ESD) is an endoscopic technique aiming to achieve en-bloc resection of mucosal neoplastic lesion in the gastrointestinal tract. It is now considered as the standard of treatment for early gastric cancer confined to the mucosa, achieving an excellent overall survival comparable to that of surgical resection.

Important adverse events associated with gastric ESD include hemorrhage (intraoperative or delayed) and perforation. The reported incidence of intraprocedural and delayed hemorrhage of gastric ESD is generally higher than that of esophageal or colorectal ESD5. This is likely due to the rich blood supply of the stomach penetrating from the muscularis to the submucosal layer. Bleeding during ESD would result in difficulty in visualizing the correct plane of dissection from blood clots obscuring view of the endoscope. As a result, prolonged procedural time may be required to achieve hemostasis and obtain adequate view for dissection.

There are currently different options of the solution for submucosal injection during gastric ESD. Epineprhine has often been added into these solutions with the aim of causing vasoconstrictive effect and potentially reduce bleeding during the procedure. The use of epinephrine has been recommended when removing larger pedunculated polyps with endoscopic mucosal resection (EMR)6. However the exact clinical benefit of adding epinephrine during gastric ESD has not been proven in the literature. On the other hand, when larger dose of epinephrine is absorbed systemically it may rarely cause significant tachycardia and generalized vasoconstriction, putting patients at risk of myocardial infarction or cerebrovascular accident.

A retrospective propensity score analysis was previously performed in one of our Japanese center (Presented at JGCA 2019, Shizuoka). After adjustment of important confounding factors including age, sex, tumor location, specimen size, depth of tumor invasion, presence of histological ulcer or scar and operators' experience, the addition of epinephrine into submucosal solution was associated with a significantly shorter procedural time upon multivariate analysis. The mean procedural time was 72±54 minutes versus 93±62 minutes with and without epinephrine respectively. (p<0.001) With the encouraging result from a single center retrospective study, we plan to conduct a prospective multicenter randomized controlled study to confirm the benefit of adding epinephrine into the submucosal solution during gastric ESD.

Connect with a study center

  • The Chinese University of Hong Kong

    Hong Kong,
    Hong Kong

    Site Not Available

  • Ishikawa Prefecture Central Hospital

    Ishikawa,
    Japan

    Site Not Available

  • Kyoto 2nd Red Cross Hospital

    Kyoto,
    Japan

    Site Not Available

  • Osaka International Cancer Institute

    Osaka,
    Japan

    Site Not Available

  • Shizuoka Cancer Center

    Shizuoka,
    Japan

    Site Not Available

  • Kosin University Gospel Hospital

    Busan,
    Korea, Republic of

    Site Not Available

  • Changi General Hospital

    Singapore,
    Singapore

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.